查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1762533

生物製剂合约研究组织市场：产业趋势及全球预测 - 依生物製剂类型、业务规模、治疗领域和地区

Biologics Contract Research Organization Market: Industry Trends and Global Forecasts - Distribution by Type of Biologic, Scale of Operation, Therapeutic Area, and Geography
出版日期: | 出版商: Roots Analysis | 英文 235 Pages | 商品交期: 最快1-2个工作天内

价格

生物製剂合约研究组织市场：概览

今年全球生物製剂合约研究组织市场规模达 215亿美元。预计在预测期内，市场将以 13%的年复合成长率成长。

市场区隔包括根据以下参数进行的市场规模和机会分析：

生物製剂类型

  • 疫苗
  • 细胞疗法
  • 基因疗法
  • 抗体
  • 重组蛋白/胜肽
  • 其他

业务规模

  • 临床业务
  • 临床前业务

治疗领域

  • 肿瘤学
  • 心血管疾病
  • 发炎性疾病
  • 神经系统疾病
  • 其他

地区

  • 北美
  • 欧洲
  • 亚洲太平洋地区
  • 拉丁美洲
  • 中东和北非
  • 其他地区

生物製剂合约研究组织市场：成长与趋势

生物製剂是製药业成长最快的领域之一。这得益于该领域的快速创新，而创新的驱动力源于对有效和个人化药物介入的需求。然而，生物製剂的开发和临床试验是高度复杂且成本高昂的过程，需要专业知识和先进的生物加工技术。因此，许多生物製剂公司选择将其药物发现和临床研究活动外包。

生物製剂合约研究组织市场-IMG1

目前，生物製剂公司采用一种商业模式，将开发流程外包给外部服务供应商，同时仍负责药物研发。这些外部研究服务提供者是各种生物製剂合约研究组织（CRO），它们承担通常由开发公司承担的一项或多项职责。这些职责包括方案设计、试验选择或监测、报告评估以及准备向美国 FDA 提交的文件。生物製剂 CRO 的主要优势包括时间效率、成本效益、关键创新和品质创新。因此，生物製剂合约研究组织市场预计将逐步扩大，以满足生物製剂申办者日益成长的研发需求。

生物製剂合约研究组织市场：关键洞察

本报告分析了生物製剂合约研究组织市场的现状，并揭示了潜在的成长机会。主要调查结果包括：

  • 目前，160 家公司声称拥有为各类生物製剂提供合约开发服务和临床试验支援的必要能力。
  • 约 50%的合约研究组织仅提供临床服务，而 12%的合约研究组织则提供与生物製剂临床研究相关的所有服务。
  • 目前的市场格局较为分散，既有成熟的公司，也有拥有丰富产品组合支持临床前和临床研究的专业服务提供者。
  • 据估计，大型製药公司目前将其近 45%的内部研发活动外包给合约研究组织（CRO）。
  • 超过三分之二的合约研究组织位于北美和欧洲，其中许多是中小型企业。
  • 为了获得竞争优势，他们积极扩展现有能力，进一步提升各自的服务水准，并跟上不断发展的行业基准。
生物製剂合约研究组织市场-IMG2
  • 目前，生物製剂开发商评估/开发超过 8,000 种候选产品，这为生物製剂合约研究组织市场创造了机会。
  • 利害关係人对该领域的兴趣也反映在近期合作活动的增加。自2016年以来，产业参与者已与申办者和/或其他合约研究组织（CRO）签署了多份合约。
  • 近20%的CRO 提供临床和临床前规模的生物製剂研究服务。
  • 随着一站式服务需求的不断成长，行业利益相关者积极整合与生物製剂研究相关的能力，主要透过併购和内部扩张。
生物製剂合约研究组织市场-IMG3
  • 预计未来十年该市场的年复合成长率约为 13%，且在治疗领域、企业规模、生物製剂类型、最终用户和地区方面都将呈现多元化发展机会。

Biocon 合约研究组织市场参与者

  • Biocon
  • Covance
  • ICON
  • Medpace
  • Pharmaron
  • PPD
  • PRA Health Sciences
  • Syneos Health
  • Vimta Labs
  • WuXi AppTec

目录

第1章 简介

第2章 执行摘要

第3章 简介

第3章 简介

  • 章节概述
  • 生物製剂概述
  • 合约研究组织概述
  • 合约研究组织（CRO）的演变
  • 合约研究组织分类
  • CRO 提供的服务
  • 外包给 CRO 的优势
  • 外包给 CRO 的风险

第4章 外包指南

  • 章节概述
  • 生物製剂研究外包
  • 外包模式
  • 选择合适的外包模式
  • 选择 CRO 合作伙伴
  • CRO 在药物开发过程中的作用
  • 结论

第5章 市场格局

  • 章节概述
  • Biocon
  • Covance
  • ICON
  • Medpace
  • Pharmaron
  • PPD
  • PRA Health Sciences
  • Syneos Health
  • Vimta Labs
  • WuXi AppTec

第7章 基准分析

  • 章节概述
  • 调查方法
  • 基准分析：同业组

第8章 伙伴关係与合作

  • 章节概述
  • 合作模式
  • 生物製剂CRO：近期合作伙伴关係与合作

第9章 併购

第10章 吸引力与竞争力矩阵

第11章 市场预测

  • 章节概述
  • 预测研究方法与关键假设
  • 全球生物製剂 CRO 市场
  • 北美生物製剂 CRO 市场
  • 欧洲生物製剂 CRO 服务市场
  • 亚太生物製剂 CRO 服务市场
  • 拉丁美洲生物製剂 CRO 服务市场
  • 拉丁美洲生物製剂 CRO 服务市场

第12章 SWOT 分析

第13章 结论

第14章 研究笔记

第15章 附录1：表格资料

第16章 附录2：公司与组织清单

BIOLOGICS CONTRACT RESEARCH ORGANIZATION MARKET: OVERVIEW

As per Roots Analysis, the global biologics contract research organization market valued at USD 21.5 billion in the current year is anticipated to grow at a lucrative CAGR of 13% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Biologic

  • Vaccines
  • Cell Therapy
  • Gene Therapy
  • Antibodies
  • Recombinant Proteins / Peptides
  • Others

Scale of Operation

  • Clinical Operations
  • Preclinical Operations

Therapeutic Area

  • Oncological Disorders
  • Cardiovascular Disorders
  • Inflammatory Disorders
  • Neurological Disorders
  • Other Therapeutic Areas

Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and North Africa
  • Rest of the World

BIOLOGICS CONTRACT RESEARCH ORGANIZATION MARKET: GROWTH AND TRENDS

Biologics represent one of the fastest growing segments of the pharmaceutical industry. This can

be attributed to the rapid pace of innovation in this field, driven by the need for effective and personalized pharmacological interventions. However, the development and clinical testing of biologics is a highly complex and costly process that demands specialized expertise and advanced bioprocessing technologies. As a result, many biopharmaceutical companies are choosing to outsource their drug discovery and clinical research operations.

Biologics Contract Research Organization Market - IMG1

Currently, biopharmaceutical companies are embracing a business model, wherein the development processes are outsourced to external service providers, whereas the company itself is responsible for the R&D of drugs. These external research service providers are various biopharma contract research organizations (CRO) that take on one or more responsibilities typically held by a developer. Examples of such responsibilities include protocol design, selection or monitoring of investigations, evaluation of reports, and preparation of documentation for submission to the US FDA. Key advantages offered by biopharma CRO include time efficiency, cost effectiveness, key to innovation, and quality innovation. Consequently, the biologics contract research organization market is anticipated to expand gradually to fulfil the growing R&D demands of biopharmaceutical sponsors.

BIOLOGICS CONTRACT RESEARCH ORGANIZATION MARKET: KEY INSIGHTS

The report delves into the current state of the biologics contract research organization market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Presently, 160 players claim to have the necessary capabilities to offer contract research services and clinical trial support for different types of biopharmaceutical products.
  • About 50% of all the players offer only clinical services; of these, 12% CROs provide all the services associated with clinical research of biologics.
  • The current market landscape is fragmented, featuring a mix of well-established players and specialty service providers, having extensive portfolios to support preclinical and clinical research.
  • It is estimated that big pharma players presently outsource close to 45% of their internal R&D operations to CROs.
  • More than two-thirds of the contract research service providers are based in North America and Europe; most of these players are small and mid-sized companies.
  • In order to gain a competitive edge, companies are actively expanding their existing capabilities in order to further augment their respective offerings and also comply with evolving industry benchmarks.
Biologics Contract Research Organization Market - IMG2
  • Over 8,000 product candidates are currently being evaluated / under development biologic drug developers, presenting opportunities in the biologics contract research organization market.
  • The growing interest of stakeholders in this field is also reflected in the increase in partnership activity in the recent past; since 2016, industry players have signed multiple deals with sponsor and / or other CROs.
  • Close to 20% of the CROs provide research services for biologics at the clinical and preclinical scales.
  • With the rising demand for one-stop shops, industry stakeholders are actively consolidating their capabilities related to biopharmaceutical research, mostly through mergers and acquisitions, and internal expansions.
Biologics Contract Research Organization Market - IMG3
  • The market is expected to grow at a CAGR of ~13% in the coming decade; the opportunity is likely to be well distributed across therapeutic areas, scales of operation, types of biologics, end users and geographical regions.

Example Players in the Biologics Contract Research Organization Market

  • Biocon
  • Covance
  • ICON
  • Medpace
  • Pharmaron
  • PPD
  • PRA Health Sciences
  • Syneos Health
  • Vimta Labs
  • WuXi AppTec

BIOLOGICS CONTRACT RESEARCH ORGANIZATION MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global biologics contract research organization market, focusing on key market segments, including [A] type of biologic, [B] scale of operation, [C] therapeutic area and [D] geography.
  • Market Landscape: A comprehensive evaluation of the biopharmaceutical services market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] types of biologics manufactured, [E] scale of operation and [F] types of services offered (including clinical services and preclinical services).
  • Company Profiles: In-depth profiles of CROs engaged in offering biopharmaceutical related services, focusing on [A] overview of the company, [B] financial information (if available), [C] service portfolio and [D] recent developments and an informed future outlook.
  • Benchmarking Analysis: A comprehensive benchmark analysis of players engaged in biologics contract research organization market based on the [A] capabilities of companies with a peer groups with an aim to gain a competitive edge.
  • Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the biologics contract research organization market, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] most active players (in terms of number of partnerships signed), [D] scale of operation and [E] geography.
  • Mergers and Acquisitions: An in-depth analysis of the mergers and acquisitions undertaken in this domain, based on relevant parameters, such as [A] year of acquisition, [B] type of collaboration, [C] geography, [D] most active acquirers, [E] ownership change matrix, [F] key value drivers and [G] acquisition deal multiples.
  • Attractiveness Competitiveness Matrix: A comprehensive acquisition target analysis, considering the historical trend of the activity of companies that have acquired other firms since 2016, and providing a means for other industry players to identify potential acquisition targets.
  • SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of biologics contract research organization market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
    • 1.2.1. Research Assumptions
    • 1.2.2. Project Methodology
    • 1.2.3. Forecast Methodology
    • 1.2.4. Robust Quality Control
    • 1.2.5. Key Considerations
      • 1.2.5.1. Demographics
      • 1.2.5.2. Economic Factors
      • 1.2.5.3. Government Regulations
      • 1.2.5.4. Supply Chain
      • 1.2.5.5. COVID Impact / Related Factors
      • 1.2.5.6. Market Access
      • 1.2.5.7. Healthcare Policies
      • 1.2.5.8. Industry Consolidation
  • 1.3 Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3 Introduction

  • 3.1. Chapter Overview
  • 3.2. Overview of Biologics
    • 3.2.1. Types of Biologics
  • 3.3. Overview of Contract Research Organizations (CROs)
  • 3.4. Evolution of CROs
  • 3.5. Classification of CROs
  • 3.6. Services Offered by CROs
  • 3.7. Advantages of Outsourcing Operations to CROs
  • 3.8. Risks Associated with Outsourcing Operations to CROs

4. GUIDE TO OUTSOURCING

  • 4.1. Chapter Overview
  • 4.2. Outsourcing Biologics Research
  • 4.3. Models of Outsourcing
    • 4.3.1. Transactional Outsourcing Model
    • 4.3.2. Performance / Outcome-based Business Model
    • 4.3.3. Staff Augmentation Model
    • 4.3.4. Phase-Dependent Outsourcing Model
  • 4.4. Selecting an Appropriate Outsourcing Model
    • 4.4.1. Hybrid Approach
  • 4.5. Selecting a CRO Partner
    • 4.5.1. Key Considerations for Outsourcing Biologics-related Operations
  • 4.6. Role of CROs in the Drug Development Process
    • 4.6.1. Discovery and Preclinical Research
    • 4.6.2. Early Clinical Research
    • 4.6.3. Clinical Research and Laboratory Services
  • 4.7. Conclusion

5. MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Biopharmaceutical CROs: Overall Market Landscape
    • 5.2.1. Analysis by Year of Establishment, Company Size and Location of Headquarters
    • 5.2.2. Analysis by Scale of Operation
  • 5.3. Preclinical Biopharmaceutical CROs
    • 5.3.1. Analysis by Year of Establishment
    • 5.3.2. Analysis by Company Size
    • 5.3.3. Analysis by Location of Headquarters
    • 5.3.4. Analysis by Type of Biologic
    • 5.3.5. Analysis by Type of Services Offered
  • 5.4. Clinical Biopharmaceutical CROs
    • 5.4.1. Analysis by Year of Establishment
    • 5.4.2. Analysis by Company Size
    • 5.4.3. Analysis by Location of Headquarters
    • 5.4.4. Analysis by Type of Biologics
    • 5.4.5. Analysis by Type of Services Offered

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Biocon
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Services Portfolio
    • 6.2.4. Future Outlook
  • 6.3. Covance
    • 6.3.1. Company Overview
    • 6.3.2. Service Portfolio
    • 6.3.3. Financial Information
    • 6.3.4. Future Outlook
  • 6.4. ICON
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Service Portfolio
    • 6.4.4. Future Outlook
  • 6.5. Medpace
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
    • 6.5.3. Service Portfolio
    • 6.5.4. Future Outlook
  • 6.6. Pharmaron
    • 6.6.1. Company Overview
    • 6.6.2. Services Portfolio
    • 6.6.3. Future Outlook
  • 6.7. PPD
    • 6.7.1. Company Overview
    • 6.7.2. Service Portfolio
    • 6.7.3. Financial Information
    • 6.7.4. Future Outlook
  • 6.8. PRA Health Sciences
    • 6.8.1. Company Overview
    • 6.8.2. Financial Information
    • 6.8.3. Service Portfolio
    • 6.8.4. Future Outlook
  • 6.9. Syneos Health
    • 6.9.1. Company Overview
    • 6.9.2. Financial Information
    • 6.9.3. Services Portfolio
    • 6.9.4. Future Outlook
  • 6.10. Vimta Labs
    • 6.10.1. Company Overview
    • 6.10.2. Services Portfolio
    • 6.10.3. Financial Information
    • 6.10.4. Future Outlook
  • 6.11. WuXi AppTec
    • 6.11.1. Company Overview
    • 6.11.2. Financial Information
    • 6.11.3. Service Portfolio
    • 6.11.4. Future Outlook

7. BENCHMARK ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Methodology
  • 7.3. Benchmark Analysis: Peer Groups
    • 7.3.1. Peer Group I
    • 7.3.2. Peer Group II
    • 7.3.3. Peer Group III
    • 7.3.4. Peer Group IV
    • 7.3.5. Peer Group V
    • 7.3.6. Peer Group VI
    • 7.3.7. Peer Group VII
    • 7.3.8. Peer Group VIII

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Biopharmaceutical CROs: Recent Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership Model
      • 8.3.2.1. Analysis by Year of Partnership and Type of Partnership Model
    • 8.3.3. Most Active Players: Analysis by Number of Partnerships
    • 8.3.4. Analysis by Scale of Operation
    • 8.3.5. Analysis by Geography
      • 8.3.5.1. Country-wise Analysis
      • 8.3.5.2. Intercontinental and Intracontinental Agreements

9. MERGERS AND ACQUISITIONS

  • 9.1. Chapter Overview
  • 9.2. Merger and Acquisition Models
  • 9.3. Biopharmaceutical CROs: Mergers and Acquisitions
    • 9.3.1. Analysis by Year of Acquisition
    • 9.3.2. Analysis by Type of Collaboration
    • 9.3.3. Analysis by Geography
      • 9.3.3.1. Continent-wise Distribution
      • 9.3.3.2. Country-wise Distribution
    • 9.3.4. Ownership Change Matrix
    • 9.3.5. Most Active Acquirers: Analysis by Number of Acquisitions
  • 9.4. Distribution by Key Value Drivers
    • 9.4.1. Analysis by Key Value Drivers
    • 9.4.2. Analysis by Key Value Drivers and Year of Acquisitions
  • 9.5. Valuation Analysis: Acquisition Deal Multiples

10. ATTRACTIVENESS COMPETATIVENESS MATRIX

  • 10.1. Chapter Overview
  • 10.2. AC Matrix: Overview
    • 10.2.1. Strong Business Segment
    • 10.2.2. Average Business Segment
    • 10.2.3. Weak Business Segment
  • 10.3. Analytical Methodology
  • 10.4. AC Matrix: Contract Manufacturing Scenario in North America
  • 10.5. AC Matrix: Contract Manufacturing Scenario in Europe
  • 10.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East

11. MARKET FORECAST

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology and Key Assumptions
  • 11.3. Global Biopharmaceutical CROs Market
    • 11.3.1. Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
    • 11.3.2. Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
    • 11.3.3. Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
    • 11.3.4. Global Biopharmaceutical CROs Market: Distribution by Geography
  • 11.4. Biopharmaceutical CROs Market in North America
    • 11.4.1. Biopharmaceutical CROs Market in North America: Distribution by Therapeutic Area
      • 11.4.1.1. Biopharmaceutical CROs Market for Oncological Disorders in North America, Till 2035
      • 11.4.1.2. Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Till 2035
      • 11.4.1.3. Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Till 2035
      • 11.4.1.4. Biopharmaceutical CROs Market for Neurological Disorders in North America, Till 2035
      • 11.4.1.5. Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Till 2035
    • 11.4.2. Biopharmaceutical CROs Market in North America: Distribution by Scale of Operation
      • 11.4.2.1. Biopharmaceutical CROs Market for Preclinical Operations in North America, Till 2035
      • 11.4.2.2. Biopharmaceutical CROs Market for Clinical Operations in North America, Till 2035
  • 11.5. Biopharmaceutical CRO Services Market in Europe
    • 11.5.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Europe
      • 11.5.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Europe, Till 2035
      • 11.5.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Europe, Till 2035
      • 11.5.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Europe, Till 2035
      • 11.5.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Europe, Till 2035
      • 11.5.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Europe, Till 2035
    • 11.5.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Europe
      • 11.5.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Europe, Till 2035
      • 11.5.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Europe, Till 2035
  • 11.6. Biopharmaceutical CRO Services Market in Asia-Pacific
    • 11.6.1. Biopharmaceutical CRO Services Market: Distribution by Therapeutic Area in Asia-Pacific
      • 11.6.1.1. Biopharmaceutical CRO Services Market for Oncological Disorders in Asia-Pacific, Till 2035
      • 11.6.1.2. Biopharmaceutical CRO Services Market for Cardiovascular Disorders in Asia-Pacific, Till 2035
      • 11.6.1.3. Biopharmaceutical CRO Services Market for Inflammatory Disorders in Asia-Pacific, Till 2035
      • 11.6.1.4. Biopharmaceutical CRO Services Market for Neurological Disorders in Asia-Pacific, Till 2035
      • 11.6.1.5. Biopharmaceutical CRO Services Market for Other Therapeutic Areas in Asia-Pacific, Till 2035
    • 11.6.2. Biopharmaceutical CRO Services Market: Distribution by Scale of Operation in Asia-Pacific
      • 11.6.2.1. Biopharmaceutical CRO Services Market for Preclinical Operations in Asia-Pacific, Till 2035
      • 11.6.2.2. Biopharmaceutical CRO Services Market for Clinical Operations in Asia-Pacific, Till 2035
  • 11.7. Biopharmaceutical CRO Services Market in Latin America
  • 11.8. Biopharmaceutical CRO Services Market in Middle East North America

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weaknesses
  • 12.4. Opportunities
  • 12.5. Threats
  • 12.6. Comparison of SWOT Factors

13. CONCLUDING REMARKS

  • 13.1. Chapter Overview

14. SURVEY TRANSCRIPTS

15. APPENDIX I: TABULATED DATA

16. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 4.1 Attributes of Transactional Outsourcing Based Business Model
  • Table 4.2 Comparison of Key Factors Considered by Biologic Developers for Selecting a CRO Partner: Harvey Ball Analysis
  • Table 5.1 Biopharmaceutical CROs: Information on Year of Establishment, Location of Headquarters, Company Size and Types of Biologics
  • Table 5.2 Biopharmaceutical Preclinical CROs: Information on Types of Services Offered
  • Table 5.3 Biopharmaceutical Clinical CROs: Information on Types of Services Offered
  • Table 6.1 Biocon: Company Overview
  • Table 6.2 Biocon: Future Outlook
  • Table 6.3 Covance: Company Overview
  • Table 6.4 Covance: Future Outlook
  • Table 6.5 ICON: Company Overview
  • Table 6.6 ICON: Future Outlook
  • Table 6.7 Medpace: Company Overview
  • Table 6.8 Medpace: Future Outlook
  • Table 6.9 Pharmaron: Company Overview
  • Table 6.10 Pharmaron: Future Outlook
  • Table 6.11 PPD: Company Overview
  • Table 6.12 PPD: Future Outlook
  • Table 6.13 PRA Health Sciences: Company Overview
  • Table 6.14 PRA Health Sciences: Future Outlook
  • Table 6.15 Syneos Health: Company Overview
  • Table 6.16 Syneos Health: Future Outlook
  • Table 6.17 VIMTA Labs: Company Overview
  • Table 6.18 WuXi App-Tec: Company Overview
  • Table 6.19 WuXi App Tec: Future Outlook
  • Table 7.1 Benchmark Analysis: Peer Groups
  • Table 8.1 Partnerships and Collaborations: List of Agreements, Since 2016
  • Table 9.1 Mergers and Acquisitions: List of Mergers / Acquisitions, Since 2016
  • Table 9.2 Mergers and Acquisitions: Information on Key Value Drivers, Since 2016
  • Table 9.3 Mergers and Acquisitions: Deal Multiples, Since 2016
  • Table 15.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Table 15.2 Biopharmaceutical CROs: Distribution by Scale of Operation
  • Table 15.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
  • Table 15.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
  • Table 15.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
  • Table 15.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
  • Table 15.8 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
  • Table 15.9 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
  • Table 15.10 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types Services Offered
  • Table 15.11 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
  • Table 15.12 Biopharmaceutical Clinical CROs: Distribution by Company Size
  • Table 15.13 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
  • Table 15.14 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
  • Table 15.15 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
  • Table 15.16 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
  • Table 15.17 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
  • Table 15.18 Biocon: Annual Service Revenues, Since 2016 (INR Billion)
  • Table 15.19 Covance: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.20 ICON: Annual Revenues, Since 2016 (USD Billion)
  • Table 15.21 Medpace: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.22 PPD: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.23 PRA Health Sciences: Annual Revenues, Since 2016 (USD Billion)
  • Table 15.24 Syneos: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.25 Vimta Labs: Annual Service Revenues, Since 2016 (INR Billion)
  • Table 15.26 WuXi AppTec: Annual Service Revenues, Since 2016 (USD Billion)
  • Table 15.27 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 15.28 Partnerships and Collaborations: Distribution by Type of Partnership Model
  • Table 15.29 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
  • Table 15.30 Most Active Players: Distribution by Number of Partnerships
  • Table 15.31 Partnerships and Collaborations: Distribution by Scale of Operation
  • Table 15.32 Partnerships and Collaborations: Distribution by Geography
  • Table 15.33 Partnerships and Collaborations: Country-Wise Distribution
  • Table 15.34 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 15.35 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (Since 2016)
  • Table 15.36 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
  • Table 15.37 Mergers and Acquisitions: Distribution by Year and Type of Agreement
  • Table 15.38 Mergers and Acquisitions: Continent-wise Distribution
  • Table 15.39 Mergers and Acquisitions: Continent-wise Distribution
  • Table 15.40 Mergers and Acquisitions: Country-wise Distribution
  • Table 15.41 Mergers and Acquisitions: Ownership Change Matrix
  • Table 15.42 Mergers and Acquisitions: Key Value Drivers
  • Table 15.43 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Table 15.44 Mergers and Acquisitions: Deal Multiples Based on Revenue
  • Table 15.45 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
  • Table 15.46 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
  • Table 15.47 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
  • Table 15.48 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
  • Table 15.49 Global Biopharmaceutical CROs Market: Distribution by Geography
  • Table 15.50 Biopharmaceutical CROs Market in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.51 Biopharmaceutical CROs Market for Oncological Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.52 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.53 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.54 Biopharmaceutical CROs Market for Neurological Disorders in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.55 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.56 Biopharmaceutical CROs Market for Preclinical Operations in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.57 Biopharmaceutical CROs Market for Clinical Operations in North America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.58 Biopharmaceutical CROs Market in Europe, Till 2035 (USD Million)
  • Table 15.59 Biopharmaceutical CROs Market for Oncological Disorders in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.60 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, Till 2035 (USD Million)
  • Table 15.61 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.62 Biopharmaceutical CROs Market for Neurological Disorders in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.63 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.64 Biopharmaceutical CROs Market for Preclinical Operations in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.65 Biopharmaceutical CROs Market for Clinical Operations in Europe, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.66 Biopharmaceutical CROs Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.67 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.68 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.69 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.70 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.71 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.72 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.73 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.74 Biopharmaceutical CROs Market for Preclinical Operations in Latin America, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.75 Biopharmaceutical CROs Market for Preclinical Operations in Middle East North Africa, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
  • Table 15.76 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures

  • Figure 3.1 Types of Biologics
  • Figure 3.2 Stages of the Drug Development Process
  • Figure 3.3 Commonly Offered Services by CROs
  • Figure 3.4 Advantages of Outsourcing Operations to CROs
  • Figure 3.5 Risks Associated with Outsourcing Operations to CROs
  • Figure 4.1 Guiding Models for Outsourcing
  • Figure 4.2 Key Characteristics of Transactional Outsourcing Model
  • Figure 4.3 Key Characteristics of Performance / Outcome based Business Model
  • Figure 4.4 Steps to Consider before Outsourcing
  • Figure 4.5 Key Considerations while Selecting a CRO Partner
  • Figure 4.6 Role of CROs in the Drug Development Process
  • Figure 5.1 Biopharmaceutical CROs: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Figure 5.2 Biopharmaceutical CROs: Distribution by Scale of Operation
  • Figure 5.3 Biopharmaceutical Preclinical CROs: Distribution by Year of Establishment
  • Figure 5.4 Biopharmaceutical Preclinical CROs: Distribution by Company Size
  • Figure 5.5 Biopharmaceutical Preclinical CROs Distribution by Location of Headquarters
  • Figure 5.6 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics
  • Figure 5.7 Biopharmaceutical Preclinical CROs: Distribution by Types of Services Offered
  • Figure 5.8 Biopharmaceutical Preclinical CROs: Distribution by Number of Services Offered
  • Figure 5.9 Biopharmaceutical Preclinical CROs: Distribution by Types of Biologics and Types of Services Offered
  • Figure 5.10 Biopharmaceutical Clinical CROs: Distribution by Year of Establishment
  • Figure 5.11 Biopharmaceutical Clinical CROs: Distribution by Company Size
  • Figure 5.12 Biopharmaceutical Clinical CROs: Distribution by Location of Headquarters
  • Figure 5.13 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics
  • Figure 5.14 Biopharmaceutical Clinical CROs: Distribution by Types of Services Offered
  • Figure 5.15 Biopharmaceutical Clinical CROs: Distribution by Number of Services Offered
  • Figure 5.16 Biopharmaceutical Clinical CROs: Distribution by Types of Biologics and Types of Services Offered
  • Figure 6.1 Biocon: Annual Services Revenues, Since 2016 (INR Billion)
  • Figure 6.2 Biocon: Service Portfolio
  • Figure 6.3 Covance: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.4 Covance: Service Portfolio
  • Figure 6.5 ICON: Annual Revenues, Since 2016 (USD Billion)
  • Figure 6.6 ICON: Service Portfolio
  • Figure 6.7 Medpace: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.8 Medpace: Service Portfolio
  • Figure 6.9 Medpace: Regulatory Affair Capabilities
  • Figure 6.10 Pharmaron: Service Portfolio
  • Figure 6.11 PPD: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.12 PPD: Service Portfolio
  • Figure 6.13 PRA Health Sciences: Annual Revenues, Since 2016 (USD Billion)
  • Figure 6.14 PRA Health Sciences: Service Portfolio
  • Figure 6.15 Syneos Health: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.16 Syneos Health: Service Portfolio
  • Figure 6.17 Vimta Labs: Annual Service Revenues, Since 2016 (INR Billion)
  • Figure 6.18 Vimta Labs: Service Portfolio
  • Figure 6.19 WuXi App Tec: Annual Services Revenues, Since 2016 (USD Billion)
  • Figure 6.20 WuXi App Tec: Service Portfolio
  • Figure 7.1 Benchmark Analysis: Distribution by Company Size and Location of Headquarters
  • Figure 7.2 Benchmark Analysis: Peer Group I
  • Figure 7.3 Benchmark Analysis: Peer Group II
  • Figure 7.4 Benchmark Analysis: Peer Group III
  • Figure 7.5 Benchmark Analysis: Peer Group IV
  • Figure 7.6 Benchmark Analysis: Peer Group V
  • Figure 7.7 Benchmark Analysis: Peer Group VI
  • Figure 7.8 Benchmark Analysis: Peer Group VII
  • Figure 7.9 Benchmark Analysis: Peer Group VIII
  • Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership Model
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership Model
  • Figure 8.4 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.5 Partnerships and Collaborations: Distribution by Scale of Operation
  • Figure 8.6 Partnerships and Collaborations: Distribution by Geography
  • Figure 8.7 Partnerships and Collaborations: Country-Wise Distribution
  • Figure 8.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1 Mergers and Acquisitions: Distribution by Year of Merger / Acquisition (Since 2016)
  • Figure 9.2 Mergers and Acquisitions: Distribution by Type of Merger / Acquisition
  • Figure 9.3 Mergers and Acquisitions: Distribution by Year and Type of Merger / Acquisition
  • Figure 9.4 Mergers and Acquisitions: Continent-wise Distribution
  • Figure 9.5 Mergers and Acquisitions: Region-wise Distribution
  • Figure 9.6 Mergers and Acquisitions: Country-wise Distribution
  • Figure 9.7 Mergers and Acquisitions: Ownership Change Matrix
  • Figure 9.8 Mergers and Acquisitions: Key Value Drivers
  • Figure 9.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Figure 9.10 Mergers and Acquisitions: Deal Multiples Based on Revenue
  • Figure 9.11 Mergers and Acquisitions: Deal Multiples Based on Year of Experience
  • Figure 10.1. AC Matrix: Pictorial Representation
  • Figure 10.2. AC Matrix: Positioning of Different Biologics in North America
  • Figure 10.3. AC Matrix: Positioning of Different Biologics in Europe
  • Figure 10.4. AC Matrix: Positioning of Different Biologics in Asia Pacific
  • Figure 11.1 Biopharmaceutical CROs: Market Forecast Methodology
  • Figure 11.2 Global Biopharmaceutical CROs Market, Till 2035
  • Figure 11.3 Global Biopharmaceutical CROs Market: Distribution by Types of Biologics
  • Figure 11.4 Global Biopharmaceutical CROs Market: Distribution by Therapeutic Area
  • Figure 11.5 Global Biopharmaceutical CROs Market: Distribution by Scale of Operation
  • Figure 11.6 Global Biopharmaceutical CROs Market: Distribution by Geography
  • Figure 11.7 Biopharmaceutical CROs Market in North America, Till 2035 (USD Million)
  • Figure 11.8 Biopharmaceutical CROs Market for Oncological Disorders in North America, Till 2035 (USD Million)
  • Figure 11.9 Biopharmaceutical CROs Market for Cardiovascular Disorders in North America, Till 2035 (USD Million)
  • Figure 11.10 Biopharmaceutical CROs Market for Inflammatory Disorders in North America, Till 2035 (USD Million)
  • Figure 11.11 Biopharmaceutical CROs Market for Neurological Disorders in North America, Till 2035 (USD Million)
  • Figure 11.12 Biopharmaceutical CROs Market for Other Therapeutic Areas in North America, Till 2035 (USD Million)
  • Figure 11.13 Biopharmaceutical CROs Market for Preclinical Operations in North America, Till 2035 (USD Million)
  • Figure 11.14 Biopharmaceutical CROs Market for Clinical Operations in North America, Till 2035 (USD Million
  • Figure 11.15 Biopharmaceutical CROs Market in Europe, Till 2035 (USD Million)
  • Figure 11.16 Biopharmaceutical CROs Market for Oncological Disorders in Europe, Till 2035 (USD Million)
  • Figure 11.17 Biopharmaceutical CROs Market for Cardiovascular Disorders in Europe, Till 2035 (USD Million)
  • Figure 11.18 Biopharmaceutical CROs Market for Inflammatory Disorders in Europe, Till 2035 (USD Million)
  • Figure 11.19 Biopharmaceutical CROs Market for Neurological Disorders in Europe, Till 2035 (USD Million)
  • Figure 11.20 Biopharmaceutical CROs Market for Other Therapeutic Areas in Europe, Till 2035 (USD Million)
  • Figure 11.21 Biopharmaceutical CROs Market for Preclinical Operations in Europe, Till 2035 (USD Million)
  • Figure 11.22 Biopharmaceutical CROs Market for Clinical Operations in Europe, Till 2035 (USD Million)
  • Figure 11.23 Biopharmaceutical CROs Market in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.24 Biopharmaceutical CROs Market for Oncological Disorders in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.25 Biopharmaceutical CROs Market for Cardiovascular Disorders in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.26 Biopharmaceutical CROs Market for Inflammatory Disorders in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.27 Biopharmaceutical CROs Market for Neurological Disorders in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.28 Biopharmaceutical CROs Market for Other Therapeutic Areas in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.29 Biopharmaceutical CROs Market for Preclinical Operations in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.30 Biopharmaceutical CROs Market for Clinical Operations in Asia-Pacific, Till 2035 (USD Million)
  • Figure 11.31 Biopharmaceutical CROs Market in Latin America, Till 2035 (USD Million)
  • Figure 11.32 Biopharmaceutical CROs Market in Middle East North Africa, Till 2035 (USD Million)
  • Figure 11.33 Biopharmaceutical CROs Market: Conservative, Base and Optimistic Scenarios (USD Million)
  • Figure 12.1 Biopharmaceutical CROs SWOT Analysis: Overview
  • Figure 12.2 Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 13.1 Concluding Remarks: Current Market Landscape for Preclinical Biopharmaceutical CROs
  • Figure 13.2 Concluding Remarks: Current Market Landscape for Clinical Biopharmaceutical CROs
  • Figure 13.3 Concluding Remarks: Recent Partnerships
  • Figure 13.4 Concluding Remarks: Mergers and Acquisitions
  • Figure 13.5 Concluding Remarks: Clinical Trial Analysis
  • Figure 13.6 Concluding Remarks: Market Sizing and Opportunity Analysis